HTL Stock Overview
Develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for HTL from our risk checks.
Hamilton Thorne Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.25 |
| 52 Week High | CA$2.25 |
| 52 Week Low | CA$1.14 |
| Beta | 0.41 |
| 11 Month Change | 0.90% |
| 3 Month Change | 7.66% |
| 1 Year Change | 80.00% |
| 33 Year Change | 4.65% |
| 5 Year Change | 114.29% |
| Change since IPO | 492.11% |
Recent News & Updates
Recent updates
A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb
Jul 29
These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well
Aug 15At CA$1.40, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?
May 25Is Hamilton Thorne (CVE:HTL) Using Too Much Debt?
Mar 30These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Safely
Oct 05Should You Think About Buying Hamilton Thorne Ltd. (CVE:HTL) Now?
Jun 10Hamilton Thorne (CVE:HTL) Will Be Hoping To Turn Its Returns On Capital Around
May 15Is Hamilton Thorne (CVE:HTL) A Risky Investment?
Apr 12Estimating The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)
Mar 15When Should You Buy Hamilton Thorne Ltd. (CVE:HTL)?
Mar 01Has Hamilton Thorne (CVE:HTL) Got What It Takes To Become A Multi-Bagger?
Feb 01Announcing: Hamilton Thorne (CVE:HTL) Stock Soared An Exciting 590% In The Last Five Years
Jan 19Are Insiders Selling Hamilton Thorne Ltd. (CVE:HTL) Stock?
Jan 06What Did Hamilton Thorne's (CVE:HTL) CEO Take Home Last Year?
Dec 24
We Think Hamilton Thorne (CVE:HTL) Can Stay On Top Of Its Debt
Dec 12Is It Time To Consider Buying Hamilton Thorne Ltd. (CVE:HTL)?
Nov 30A Look At The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)
Nov 17Shareholder Returns
| HTL | CA Medical Equipment | CA Market | |
|---|---|---|---|
| 7D | 0.4% | 4.5% | 0.7% |
| 1Y | 80.0% | 6.1% | 21.7% |
Return vs Industry: HTL exceeded the Canadian Medical Equipment industry which returned 3.7% over the past year.
Return vs Market: HTL exceeded the Canadian Market which returned 21.4% over the past year.
Price Volatility
| HTL volatility | |
|---|---|
| HTL Average Weekly Movement | 1.6% |
| Medical Equipment Industry Average Movement | 13.4% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: HTL has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: HTL's weekly volatility has decreased from 8% to 2% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Kate Torchilin | www.hamiltonthorne.ltd |
Hamilton Thorne Ltd. develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets. The company offers precision laser systems and imaging systems for biology markets. It also provides test laboratory and endotoxin testing services, as well as sperm assays, including Sperm Motility Index and Sperm Penetration; and fresh and cryopreserved mouse embryos supply, and technician training and proficiency testing services.
Hamilton Thorne Ltd. Fundamentals Summary
| HTL fundamental statistics | |
|---|---|
| Market cap | CA$346.28m |
| Earnings (TTM) | -CA$2.92m |
| Revenue (TTM) | CA$106.67m |
3.2x
P/S Ratio-118.5x
P/E RatioIs HTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HTL income statement (TTM) | |
|---|---|
| Revenue | US$76.30m |
| Cost of Revenue | US$37.45m |
| Gross Profit | US$38.85m |
| Other Expenses | US$40.94m |
| Earnings | -US$2.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 50.92% |
| Net Profit Margin | -2.74% |
| Debt/Equity Ratio | 29.9% |
How did HTL perform over the long term?
See historical performance and comparison